CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This was a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. Enroll...
Phase 3
Jacksonville, Florida, United States and 107 other locations
Phase 1/2 dose escalation study to assess the safety and tolerability of ARV-110 in men with mCRPC who have progressed on prior approved systemic the...
Phase 1, Phase 2
Fleming Island, Florida, United States and 53 other locations
of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate...
Phase 2
Jacksonville, Florida, United States and 16 other locations
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutam...
Phase 2
Jacksonville, Florida, United States and 220 other locations
of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate...
Jacksonville, Florida, United States and 29 other locations
The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate...
Phase 3
Jacksonville, Florida, United States and 388 other locations
prednisone in treating patients with castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate...
Phase 3
Jacksonville, Florida, United States and 538 other locations
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA...
Phase 3
Jacksonville, Florida, United States and 394 other locations
Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.BCR means tha ...
Phase 3
Jacksonville, Florida, United States and 258 other locations
Study CP-MGC018-03 is an open-label, two-part, Phase 2 study. Part 1 of the study will enroll participants with metastatic castration-resistant prostate...
Phase 2
Jacksonville, Florida, United States and 61 other locations
Clinical trials
Research sites
Resources
Legal